Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

NCT02536196 is registered in ClinicalTrials.gov with Keystone Heart as lead sponsor.

NCT NCT02536196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02536196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
Lead sponsor
Keystone Heart
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2016
Completion date
June 30, 2019
Enrollment
478 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic aortic stenosis